NORTH PALM BEACH, Fla., June  23, 2026  (GLOBE NEWSWIRE) -- SRX Global, Inc. (NYSE:SRXH) (the &#34;Company&#34;, or &#34;SRX&#34;) today announced a strategic investment in ARMR Sciences, a clinical-stage biodefense

SRXH

SRX Global Makes Strategic Investment in Clinical-Stage Biodefense Company, ARMR Sciences

SRXH Bets on ARMR Sciences in Fentanyl Defense Platform

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>NORTH PALM BEACH, Fla., June  23, 2026  (GLOBE NEWSWIRE) -- SRX Global, Inc. (NYSE:SRXH) (the &amp;#34;Company&amp;#34;, or &amp;#34;SRX&amp;#34;) today announced a strategic investment in ARMR Sciences, a clinical-stage biodefense</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>SRX Global disclosed a strategic investment in ARMR Sciences, a clinical-stage biodefense company behind ARMR-100. Early results show an anti-fentanyl immune response with favorable safety, with the goal of providing 6-12 months of protection in healthy adults. A later 2026 phase aims to evaluate broader fentanyl protection, offering SRXH potential upside via partnership callbacks despite elevated early-stage risk.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>SRXH announces strategic investment in ARMR Sciences, a biodefense biotech.</li><li>ARMR-100 shows anti-fentanyl immune response with favorable safety in humans.</li><li>ARMR-100 targets 6-12 month protection; Phase 1/2; next phase in 2026.</li><li>Potential collaboration value; regulatory and execution risks exist.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>SRX Global, Inc. (SRXH)</strong>: Strategic investor; potential expansion of biotech partnerships and pipeline exposure.</li><li><strong>ARMR Sciences (ARMR)</strong>: Private company; ARMR-100 milestone data could unlock collaboration value with SRXH.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>Category: Corporate Developments. Fits as a strategic investment with potential value creation through external biotech collaborations, providing a near-to-medium-term catalyst while carrying execution and regulatory risks typical of early-stage programs.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>SRXH&#039;s strategic investment signals potential value creation via biotech partnerships.</li><li>ARMR-100 progress and 2026 catalysts could lift sentiment on SRXH.</li><li>Early-stage program implies high execution risk and regulatory uncertainty.</li><li>No immediate revenue impact; valuation hinges on ARMR milestones.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Date of press release: June 23, 2026.</li><li>ARMR Sciences lead product: ARMR-100; anti-fentanyl antibodies generated in humans.</li><li>ARMR-100 durability target: 6-12 months in healthy adults.</li><li>Next phase: evaluation of fentanyl protection to begin later in 2026.</li><li>SRX Global, Inc. (SRXH) announced strategic investment in ARMR Sciences.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Positive ARMR milestones could lift SRXH shares within 6–12 months if results impress.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p align="justify">NORTH PALM BEACH, Fla., June  23, 2026  (GLOBE NEWSWIRE) -- SRX Global, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/quote/SRXH">SRXH</a>) (the &#34;Company&#34;, or "SRX") today announced a strategic investment in ARMR Sciences, a clinical-stage biodefense company developing a platform of medical countermeasures against synthetic drugs, such as fentanyl. ARMR’s lead product, ARMR-100, recently announced it has successfully generated an anti-fentanyl immune response in humans and showed favorable safety data. This marks a critical milestone in the company&#39;s path toward demonstrating that this response can protect against fentanyl.</p>  <p align="justify">ARMR-100 is being designed to work with the body to generate a protective immune response. The product, in a Phase 1/2 clinical trial, produces anti-fentanyl antibodies capable of binding to lethal synthetic drugs. Once the antibodies bind to the synthetic drug target, such as fentanyl, the drug is prevented from entering the brain. If the molecule is prevented from reaching the brain, then the downstream effects that lead to overdose may also be prevented. ARMR-100 is in development to be the first long-lasting preventive medication against fentanyl, with the goal that the product endures for 6-12 months in healthy adults. The next phase is evaluating protection against fentanyl, currently on track to begin later in 2026.</p>  <p align="justify">&#34;I want to thank the entire team at SRX Global for their investment and belief in our vision, turning what many called impossible into a reality,&#34; said Collin Gage, CEO of ARMR Sciences. &#34;Our recently announced positive early results are a testament to the deeply experienced team of scientists, researchers, and medical professionals we have assembled. While there is still important work ahead, we believe today&#39;s milestone further validates our approach and reinforces our confidence in the path forward as we continue advancing a potential solution that could save countless lives. We look forward to a great partnership with SRX going forward.&#34;</p>  <p align="justify"><strong>About ARMR Sciences</strong><br></br>ARMR Sciences is a clinical-stage biodefense company developing a platform of medical countermeasures against synthetic drugs, including fentanyl, and other emerging chemical threats. The company&#39;s lead product, ARMR-100, is designed to generate a protective immune response that produces antibodies capable of binding synthetic molecules and blocking them from reaching the brain.</p>  <p align="justify">For more information, visit <a href="https://www.globenewswire.com/Tracker?data=GNPFRGUMgSohIgavsBCWdsEKiRSxhSgowR6G7Bw7mu2WcU-gnVpxpXI6pymceDYMflzVPxZC28iA3PuJuHX800KCUeYXYzYOJ0XkRIZ-Pmg=" rel="nofollow" target="_blank">https://armrsciences.com</a></p>  <p align="justify"><strong>Forward-Looking Statements </strong><br></br>This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as &#34;believe,&#34; &#34;expect,&#34; &#34;intend,&#34; &#34;aim,&#34; &#34;plan,&#34; &#34;may,&#34; &#34;could,&#34; &#34;target,&#34; and similar expressions are intended to identify forward-looking statements. These statements are based on current expectations and assumptions that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. These risks include, but are not limited to, the ability to complete the proposed transaction, shareholder approvals, market conditions, regulatory considerations, and other risks described in the Company&#39;s filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date made, and the Company undertakes no obligation to update them, except as required by law.</p>  <p><strong>Company Contact</strong><br></br>SRX Global, Inc.<br></br>Kent Cunningham, Chief Executive Officer</p>  <p><strong>Investor Relations Contact</strong><br></br>KCSA Strategic Communications<br></br>Valter Pinto, Managing Director<br></br>212-896-1254<br></br><a href="https://www.globenewswire.com/Tracker?data=WFm-Q0yZF7W8fH_yqdJ00RxzrhFaUn602iStO4riUzwdGZU0zVAExK2eVfO-UoFrdAMiOLqPKwZVu6NnWqTUUw==" rel="nofollow" target="_blank"><u>srx@kcsa.com</u></a></p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTc1MDQyNiM3NjcxOTA2IzIwOTg4MjA="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/ZDdmYmY0ZjItM2NjOC00NjI5LTk5YmUtMjE1Zjc3NmU4ZGFmLTExMTAzOTEtMjAyNi0wNi0yMy1lbg==/tiny/SRx-Health-Solutions-Inc-.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/3064f700-4805-4824-8bb3-1a323dd7ee4d"><img src="https://ml.globenewswire.com/media/3064f700-4805-4824-8bb3-1a323dd7ee4d/small/srx-logo-rgb-600x170-jpg.jpg" border="0" width="150" height="42" alt="Primary Logo"></img></a></p>

SRX Global disclosed a strategic investment in ARMR Sciences, a clinical-stage biodefense company behind ARMR-100. Early results show an anti-fentanyl immune response with favorable safety, with the goal of providing 6-12 months of protection in healthy adults. A later 2026 phase aims to evaluate broader fentanyl protection, offering SRXH potential upside via partnership callbacks despite elevated early-stage risk.

SRX Global Makes Strategic Investment in Clinical-Stage Biodefense Company, ARMR Sciences

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News